IMV101
/ Immunofoco
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 04, 2025
IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models
(ASH 2025)
- "IMV101 demonstrates high specificity of T cells transduction, potent in vitro and in vivo anti-tumor activity, effective expansion in peripheral blood of the in vivo generated CAR-T and a favorablesafety profile in murine models. This comprehensive data supports its further clinical development forboth B cell malignancies and autoimmune disease."
IO biomarker • Preclinical • Hematological Malignancies • Immunology • Infectious Disease • Pancreatic Cancer • CD34 • IFNG • IL10 • IL2 • IL6 • TNFA
1 to 1
Of
1
Go to page
1